-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria signs CRO contracts for GLP-1 animal study execution and reporting

PUBT·04/15/2026 13:13:08
Listen to the news
Lexaria signs CRO contracts for GLP-1 animal study execution and reporting
  • Lexaria signed contracts with a contract research organization to run Animal Study GLP-1-A26-1 focused on DehydraTECH-semaglutide and DehydraTECH-CBD formulations.
  • Materials sourcing began, with dosing targeted to start within about 60 days.
  • Study aims to support new patent claims, including testing alternatives to SNAC used in Novo Nordisk oral GLP-1 tablets.
  • Lexaria expects pharmacokinetic sampling over an 8-24-hour post-dose window, including measurement of drug levels in brain tissue.
  • Program will be funded from existing corporate resources.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.